Identifying Rational Immunotherapy Combinations for Glioblastoma: A Progress Report – AJMC.com Managed Markets Network
|
Identifying Rational Immunotherapy Combinations for Glioblastoma: A Progress Report
AJMC.com Managed Markets Network Leading global experts believe that for immunotherapy to work in glioblastoma (GBM)—which has an estimated 5-year survival rate of 33% in the United States—combination treatments are the way forward. This was the most important takeaway from one of … |
